Population: Immunocompromised host

An individual with an impaired immune system due to conditions such as HIV, cancer, organ transplantation, or immunosuppressive therapy

Mico-Cerda

Spain
|
2013-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection

Redjoul

France
|
2024-2024
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Vaccination

Havlin

Czechia
|
2024-2024
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Vaccination
  • Arexvy

Aguareles

Spain
|
2022-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Plitidepsin

Mikulska

Italy
|
2022-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Molnupiravir

Piñana

Spain
|
2021-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Remdesivir

Huygens

The Netherlands
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Sotrovimab
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Gentile 2

Italy
|
2023-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Infectious diseases unit
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Sotrovimab

Rotundo

Italy
|
2022-2023
  • Adults (18-64 years)
  • Fragile population
  • Immunocompromised host
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Sotrovimab
  • Molnupiravir
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Vicente-Valor

Spain
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Remdesivir

Caso

Spain
|
2022-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir

Colaneri

Italy
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Remdesivir